U.S. flag An official website of the United States government
  1. Home
  2. About FDA
  3. Reports, Manuals, & Forms
  4. Reports
  5. Budgets
  6. FY 2019 FDA Operating Plan Narrative
  1. Reports

FY 2019 FDA Operating Plan Narrative

FY 2019 FDA Operating Plan Narrative

Overview

The FY 2019 fiscal year bill provides a total program level of $5.7 billion.  The FY 2019 total funding includes $3.1 billion in budget authority and $2.6 billion in user fees. 

Budget Authority

The bill provides $3.1 billion in budget authority.  This is an increase of $184.6 million over FY 2018, which includes net increases of $11.0 million for Food Safety, and $173.6 million for Medical Product Safety, including an increase of $10.0 million in no-year funding for the 21st Century Cures Innovation Account, and $47.0 million for regulatory science, enforcement, and innovation activities to combat the opioid epidemic.  Included in the total of $47 million for Opioids, $20.0 million is set-aside to create a large-scale data warehouse to perform data analytics.  The bill also states that for the Foods program no less than $15,000,000 shall be used for inspections of foreign seafood manufacturers and field examination of import seafood.

User Fees

The bill provides $2.6 billion in user fees, including appropriating Over-the-Counter Monograph User Fee contingent upon the enactment of the Over-the-Counter-Monograph User Fee Act of 2019.

Key Initiatives

Food Safety – an increase of $11.0 million for Food Safety compared to FY 2018

  • +$2.0 million for FSMA Cooperative Grants
  • +$2.8 million for Food Import Safety
  • +$5.0 million for Strengthening Food Outbreaks
  • +$0.5 million for NARMS – Seafood
  • +$2.0 million for Standard of Identity and Product Labeling
  • +$1.5 million for Consumer Education and Outreach Regarding Biotechnology (for a total of $3.0 million)
  • -$2.8 million in savings

Medical Product Safety – an increase of $173.6 million for Medical Product Safety compared to FY 2018

  • +$47.0 million for Combatting the Opioids Epidemic
  • +$38.5 million to Promote Domestic Manufacturing
  • +$12.0 million for New Domestic Drug Industry
  • +$6.0 million MedTech Manufacturing
  • +$50.7 million for New Medical Data Enterprise
  • +$25.0 million for Growth and Transformation of Digital Health
  • +$43.3 million for New Platform for Drug Development
  • +$25.1 million for Modernizing Generic Drug Development and Review
  • +$10.0 million for Investment and Innovation for Rare Diseases
  • +$10.0 million for 21st Century Cures (for a total of $70.0 million)
  • -$94.0 million for Opioids International Mail

Facilities Activities (one-time increase)

Required Transfer: The bill directs FDA to transfer $1.5 million from FDA Headquarters (HQ) to HHS’ Office of Inspector General to support oversight of FDA’s expanded authorities.